JW (Cayman) Therapeutics Co. Ltd. (HK:2126)
:2126
Want to see HK:2126 full AI Analyst Report?
2126 Stock Chart & Stats
HK$2.50
-HK$0.02(-1.56%)
At close: 4:00 PM EST
HK$2.50
-HK$0.02(-1.56%)
Day’s Range― - ―
52-Week RangeHK$1.78 - HK$6.44
Previous CloseN/A
Volume104.00K
Average Volume (3M)2.67M
Market Cap
HK$800.12M
Enterprise ValueHK$471.66M
Total Cash (Recent Filing)HK$503.28M
Total Debt (Recent Filing)HK$262.67M
Price to Earnings (P/E)―
Beta1.83
Next Earnings
Sep 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.32
Shares Outstanding416,729,430
10 Day Avg. Volume1,852,649
30 Day Avg. Volume2,667,300
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)1.68
Price to Sales (P/S)3.39
P/FCF Ratio-11.95
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.77
Revenue Forecast (FY)HK$312.38M
Bulls Say, Bears Say
Bulls Say
Revenue Rebound & Margin ImprovementA 55% revenue rebound and ~43% gross margin in 2025 indicate improving commercial traction and a more scalable cost structure for its CAR‑T therapies. Sustained top-line growth with higher gross margins supports a path to durable unit economics and reduces dependence on financing over time.
Material Reduction In Operating Cash BurnOperating cash outflow narrowed substantially year-over-year, reflecting better cost control and working-capital management. A durable reduction in cash burn improves runway, lowers near-term refinancing pressure, and gives management more time to commercialize therapies and advance higher-margin programs.
Manageable LeverageA debt-to-equity of ~0.47 signals limited financial leverage for a development-stage biotech. This structural flexibility reduces bankruptcy risk, preserves capacity to raise incremental debt if needed, and allows more strategic use of capital for R&D and manufacturing scale-up.
Bears Say
Deep, Persistent Operating LossesVery large net losses and negative operating profitability show the business remains far from self-sustaining. Persistent negative EBIT/EBITDA increases cumulative capital needs, risks ongoing dilution from fundraising, and limits the company’s ability to invest freely in commercial expansion or withstand reimbursement pressures.
Equity Erosion Over TimeMaterial decline in shareholders' equity weakens the company’s capital buffer, reducing its ability to absorb setbacks or fund long development cycles internally. This structural depletion can raise cost of capital, increase reliance on external funding, and constrain strategic options during commercialization.
Ongoing Negative Cash Generation And Funding RelianceContinued negative free cash flow creates a structural funding requirement until profitability or cash neutrality is achieved. Dependence on external capital heightens execution risk, may force dilutive equity raises or expensive financing, and makes long-term plans vulnerable to tighter market conditions.
JW (Cayman) Therapeutics Co. Ltd. News
2126 FAQ
What was JW (Cayman) Therapeutics Co. Ltd.’s price range in the past 12 months?
JW (Cayman) Therapeutics Co. Ltd. lowest stock price was HK$1.78 and its highest was HK$6.44 in the past 12 months.
What is JW (Cayman) Therapeutics Co. Ltd.’s market cap?
JW (Cayman) Therapeutics Co. Ltd.’s market cap is HK$800.12M.
When is JW (Cayman) Therapeutics Co. Ltd.’s upcoming earnings report date?
JW (Cayman) Therapeutics Co. Ltd.’s upcoming earnings report date is Sep 01, 2026 which is in 85 days.
How were JW (Cayman) Therapeutics Co. Ltd.’s earnings last quarter?
JW (Cayman) Therapeutics Co. Ltd. released its earnings results on Mar 26, 2026. The company reported -HK$0.758 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.758.
Is JW (Cayman) Therapeutics Co. Ltd. overvalued?
According to Wall Street analysts JW (Cayman) Therapeutics Co. Ltd.’s price is currently Overvalued.
Does JW (Cayman) Therapeutics Co. Ltd. pay dividends?
JW (Cayman) Therapeutics Co. Ltd. does not currently pay dividends.
What is JW (Cayman) Therapeutics Co. Ltd.’s EPS estimate?
JW (Cayman) Therapeutics Co. Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does JW (Cayman) Therapeutics Co. Ltd. have?
JW (Cayman) Therapeutics Co. Ltd. has 416,729,430 shares outstanding.
What happened to JW (Cayman) Therapeutics Co. Ltd.’s price movement after its last earnings report?
JW (Cayman) Therapeutics Co. Ltd. reported an EPS of -HK$0.758 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4.124%.
Which hedge fund is a major shareholder of JW (Cayman) Therapeutics Co. Ltd.?
Currently, no hedge funds are holding shares in HK:2126
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
JW (Cayman) Therapeutics Co. Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
133.33%
12-Months-Change
Fundamentals
Return on Equity
-75.15%
Trailing 12-Months
Asset Growth
-38.53%
Trailing 12-Months
Company Description
JW (Cayman) Therapeutics Co. Ltd.
JW (Cayman) Therapeutics Co. Ltd, a clinical stage cell therapy company, focuses on developing, manufacturing, and commercializing cell-based immunotherapies for hematological cancers and solid tumors. The company offers cell-based immunotherapies, including CAR-T treatments, which is a treatment method that uses human immune cells to fight cancer. Its lead product candidate is Carteyva (relmacabtagene autoleucel), an anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy for the treatment of a range of hematological cancers. The company's pipeline products include JWCAR129, an autologous CAR-T therapy for the treatment of multiple myeloma; JWATM204, a TCR T-cell therapy candidate for the treatment of HCC; and JWATM203, an autologous T-cell receptor mimic T-cell therapy targeting alpha-fetoprotein for the treatment of hepatocellular carcinoma. JW (Cayman) Therapeutics Co. Ltd was founded in 2016 and is headquartered in Shanghai, the People's Republic of China.
Technical Analysis
Alphamab Oncology
―
CARsgen Therapeutics Holdings Ltd.
―
Mabpharm Limited
―
CStone Pharmaceuticals
―
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H
―
Options Prices
Currently, No data available
---